Skip to main content
Cancer Immunology, Immunotherapy : CII logoLink to Cancer Immunology, Immunotherapy : CII
. 1995 Jul;41(4):203–209. doi: 10.1007/BF01516994

Splenectomy before tumor inoculation prolongs the survival time of cachectic mice

Kuniyasu Soda 1,, Masanobu Kawakami 2, Shojirou Takagi 2, Akiyoshi Kashii 1, Michio Miyata 1
PMCID: PMC11037671  PMID: 7489562

Abstract

The effects of splenectomy on the development of cachexia, tumor growth and animal survival were studied in tumor-bearing CDF1 mice. Mice were inoculated with two subclones of colon 26 adenocarcinoma, clone 20 (with a potent capacity to induce cachexia) and clone 5 (without such activity), and underwent splenectomy before or after tumor inoculation. Splenectomy significantly prolonged the survival of mice bearing clone 20 when it was performed prior to tumor inoculation, although the progression of cachexia and tumor growth were not affected. The survival rate was higher in splenectomized than it was in nonsplenectomized mice 20–40 days after tumor inoculation. Such effects on survival were not observed, however, in mice splenectomized after inoculation with clone 20 or in mice that underwent splenectomy either before or after inoculation with clone 5. The decrease of peripheral blood lymphocyte count observed in mice bearing clone 20 was magnified when splenectomy was performed before tumor inoculation, but the serum levels of tumor necrosis factor and interleukin-6 were comparable. These results indicate that cancer death from cachexia is not directly attributable to enhanced catabolism. The mechanism by which splenectomy ameliorates the survival of cachectic mice remains to be studied, although several changes observed in the splenectomized mice after inoculation, including decreases in the peripheral blood L3T4+ cells and Lyt-2+ cells on the 9th day and 15th day respectively, and increase in the L3T4+/Lyt-2+ cell ratio on the 15th day suggest the involvement of the modified host's immune response.

Key words: Cancer cachexia, Splenectomy, Lymphocyte subset, Interleukin-6, Colon 26 adenocarcinoma

References

  • 1.Beutler B, Cerami A. Cachectin and tumor necrosis factor as two sides of the same biological coin. Nature. 1985;320:584. doi: 10.1038/320584a0. [DOI] [PubMed] [Google Scholar]
  • 2.Black K, Garrett IR, Mundy GR. Chinese hamster ovarian cells transfected with the murine interleukin-6 gene cause hypercalcemia as well as cachexia, leukocytosis and thrombocytosis in tumor-bearing nude mice. Endocrinology. 1991;128:2657. doi: 10.1210/endo-128-5-2657. [DOI] [PubMed] [Google Scholar]
  • 3.Dellon AL, Potvin C, Chretien PB. Thymus-dependent lymphocyte levels in bronchogenic carcinoma: correlations with histology, clinical stage, and clinical course after surgical treatment. Cancer. 1974;35:687. doi: 10.1002/1097-0142(197503)35:3<687::aid-cncr2820350322>3.0.co;2-u. [DOI] [PubMed] [Google Scholar]
  • 4.Dewys WD, Begg C, Lavin PT, Band PR, Bennett JM, Bertino JR, Cohen MH, Douglass HO, Jr, Engstrom PE, Ezdinli EZ, Horton J, Johnson GJ, Moertel CG, Oken MM, Perlia C, Rosenbaum C, Silverstein MN, Skeel RT, Sponzo RW, Tormey DC. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Am J Med. 1980;69:491. doi: 10.1016/s0149-2918(05)80001-3. [DOI] [PubMed] [Google Scholar]
  • 5.Evans R, Duffy TM, Kamdar SJ. Differential in situ expansion and gene expression of CD4+ and CD8+ tumor-infiltrating lymphocytes following adoptive immunotherapy in a murine tumor model system. Eur J Immunol. 1991;21:1815. doi: 10.1002/eji.1830210806. [DOI] [PubMed] [Google Scholar]
  • 6.Ge YG, Gao H, Kong XT. Changes of peripheral T-cell subsets in asplenic W256 tumor-bearing rats. J Surg Oncol. 1989;42:60. doi: 10.1002/jso.2930420113. [DOI] [PubMed] [Google Scholar]
  • 7.Gelin J, Moldawer LL, Lönnroth C, Sherry B, Chizzonite R, Lundoholm K. Role of endogenous tumor necrosis factor α and interleukin 1 for experimental tumor growth and the development of cancer cachexia. Cancer Res. 1991;51:415. [PubMed] [Google Scholar]
  • 8.Holdsworth RJ, Irving AD, Cuschieri A. Postsplenectomy sepsis and its mortality rate: actual versus perceived risk. Br J Surg. 1991;78:1031. doi: 10.1002/bjs.1800780904. [DOI] [PubMed] [Google Scholar]
  • 9.Imai S, Nio Y, Shiraishi T, Tsubono M, Morimoto H, Tseng C, Kawabata K, Masai Y, Tobe T. Effects of splenectomy on pulmonary metastasis and growth of SC42 carcinoma transplanted into mouse liver. J Surg Oncol. 1991;47:178. doi: 10.1002/jso.2930470309. [DOI] [PubMed] [Google Scholar]
  • 10.Kawakami M, Cerami A. Studies of endotoxin-induced decrease in lipoprotein lipase activity. J Exp Med. 1981;154:631. doi: 10.1084/jem.154.3.631. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Kawakami M, Ikeda Y, Le-Trang N, Vine W, Cerami A. Studies of conditions and agents that stimulate and inhibit the production of Cachectin by macrophages. In: Paton W, editor. Proceedings of IUPHAR, vol. 2. London: Macmillan; 1984. p. 377. [Google Scholar]
  • 12.Kawakami M, Watanabe N, Ogawa H, Murase T, Yamada N, Sando H, Shibata S, Oda T, Takaku F. Specificity in metabolic effects of cachectin/TNF and other related cytokines. Ann NY Acad Sci. 1990;587:339. doi: 10.1111/j.1749-6632.1990.tb00175.x. [DOI] [PubMed] [Google Scholar]
  • 13.Langstein HN, Doherty GM, Fraker DL, Buresh CM, Norton JA. The roles of γ-interferon and tumor necrosis factor α in an experimental rat model of cancer cachexia. Cancer Res. 1991;51:2302. [PubMed] [Google Scholar]
  • 14.Leibovici J, Michowitz M, Argaman H. Change in the role of the spleen from protective to harmful following tumor progression in AKR lymphoma. Invasion Metastasis. 1990;10:289. [PubMed] [Google Scholar]
  • 15.Massaioli N, Mainardi SM, Paron L, Redivo L, Rota-Scalabrini D, Poccardi G. Phenotypical characterization of lymphocyte recirculating subsets in patients undergoing splenectomy for trauma. Ann Ital Chir. 1990;61:273. [PubMed] [Google Scholar]
  • 16.McCluskey DR, Roy AD, Abram WP, Martin WMC. T lymphocyte subsets in the peripheral blood of patients with benign and malignant breast disease. Br J Cancer. 1983;47:307. doi: 10.1038/bjc.1983.41. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Mori M, Yamaguchi K, Abe K. Purification of a lipoprotein lipase-inhibiting protein produced by a melanoma cell line associated with cancer cachexia. Biochem Biophys Res Commun. 1989;160:1085. doi: 10.1016/s0006-291x(89)80114-7. [DOI] [PubMed] [Google Scholar]
  • 18.Müller C, Zielinski CC, Klepetko W, Knoflach P, Wolf H, Eibl MM. Phenotypic and functional analysis of cellular cytotoxicity after splenectomy. Int Arch Allergy Appl Immunol. 1988;87:76. doi: 10.1159/000234652. [DOI] [PubMed] [Google Scholar]
  • 19.Oliff A, Jones DD, Boyer M, Martinez D, Kiefer D, Vuocolo G, Wolfe A, Socher SH. Tumors secreting human TNF/cachectin induce cachexia in mice. Cell. 1987;50:555. doi: 10.1016/0092-8674(87)90028-6. [DOI] [PubMed] [Google Scholar]
  • 20.Ouchi FK, Tamura S, Mori K, Tanaka Y, Ishitsuka H. Establishment and characterization of cachexia inducing and noninducing clones of murine colon 26 carcinoma. Int J Cancer. 1995;61:522. doi: 10.1002/ijc.2910610416. [DOI] [PubMed] [Google Scholar]
  • 21.Shwarz RE, Hiserodt JC. Effects of splenectomy on the development of tumor-specific immunity. J Surg Res. 1990;48:448. doi: 10.1016/0022-4804(90)90011-p. [DOI] [PubMed] [Google Scholar]
  • 22.Soda K, Kawakami M, Kashii A, Miyata M. Characterization of mice bearing subclone of colon 26 adenocarcinoma disqualifies interleukin-6 as the sole inducer of cachexia. Jpn J Cancer Res. 1994;85:1124. doi: 10.1111/j.1349-7006.1994.tb02917.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Soda K, Kawakami M, Kashii A, Miyata M. Manifestations of cancer cachexia induced by colon 26 adenocarcinoma is not fully ascribable to interleukin-6. Int J Cancer. 1995;62:332. doi: 10.1002/ijc.2910620317. [DOI] [PubMed] [Google Scholar]
  • 24.Spaeth G, Specian RD, Deitch EA. Splenectomy influences endotoxin-induced bacterial translocation. J Trauma. 1990;30:1267. doi: 10.1097/00005373-199010000-00012. [DOI] [PubMed] [Google Scholar]
  • 25.Strassmann G, Fong M, Kenney JS, Jacob CO. Evidence for the involvement of interleukin 6 in experimentall cancer cachexia. J Clin Invest. 1992;89:1681. doi: 10.1172/JCI115767. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Strassmann G, Jacob CO, Evans R, Beall D, Fong M. Mechanisms of experimental cancer cachexia: interaction between mononuclear phagocytes and colon-26 carcinoma and its relevance to IL-6-mediated cancer cachexia. J Immunol. 1992;148:3674. [PubMed] [Google Scholar]
  • 27.Studnicka M, Wirnsberger R, Neumann M, Pokieser L, Angerler J. Peripheral blood lymphocyte subsets and survival in small-cell lung cancer. Chest. 1994;105:1673. doi: 10.1378/chest.105.6.1673. [DOI] [PubMed] [Google Scholar]
  • 28.Tanaka Y, Eda H, Tanaka T, Udagawa T, Ishikawa T, Horii I, Ishitsuka H, Kataoka T, Taguchi T. Experimental cancer cachexia induced by transplantable colon 26 adenocarcinoma in mice. Cancer Res. 1990;50:2290. [PubMed] [Google Scholar]
  • 29.Toyonaga M, Hiraoka T, Tanaka H, Miyauchi Y. The spleen can influence the metastasis of AH130 hepatoma cells in rats. J Surg Oncol. 1993;53:113. doi: 10.1002/jso.2930530213. [DOI] [PubMed] [Google Scholar]
  • 30.Yamaki T, Uede T, Shijubo N, Kikuchi K. Functional analysis of mononuclear cells infiltrating into tumors. III. Soluble factors involved in the regulation of T lymphocyte infiltration into tumors. J Immunol. 1988;140:4388. [PubMed] [Google Scholar]

Articles from Cancer Immunology, Immunotherapy : CII are provided here courtesy of Springer

RESOURCES